je.st

Home › combination

Tag: combination

Kingsbury, Inc. Updates Thrust-Journal Combination Bearing

2013-05-09 06:00:00| Industrial Newsroom - All News for Today

Philadelphia, PA – For the past several years, Kingsbury (<a href="http://kingsbury.com">kingsbury.com</a>) has been revamping the design of its CH System, a combination fluid-film thrust and journal bearing, that was first developed more than 75 years ago by the company’s founder himself. Dr. Kingsbury was looking for a way to simplify the use of hydrodynamic bearings on applications such as pumps, and with the CH System, he was able to eliminate the need for an external pump and ...

Tags: updates combination bearing kingsbury

T-Mobile and MetroPCS Combination Complete

2013-05-01 15:33:58| MobileTechNews

The combined company will begin trading today under the ticker "TMUS" as the company's CEO rings the bell opening trading at the NYSE in New York.

Tags: complete combination tmobile metropcs

Combination Sander-Buffer features palm-style design.

2013-05-01 14:26:33| Industrial Newsroom - All News for Today

Weighing 1.5 lb, Combination Sander/Buffer allows dual-purpose Random Orbital Sanding and Rotary Polishing. Air tool can switch from 3/16 in. random orbital pattern to fixed rotary mode with turn of switch. In orbital sander mode, 3 in. diameter tool is suitable for use on contoured surfaces and tight areas. As rotary buffer, tool runs at 12,000 rpm free speed, then slows to 4,000 rpm while in use. Adjustable speed regulator is included to fine-tune speed to specific task. This story is related to the following:Mounting and Attaching ProductsSearch for suppliers of: Orbital Sanders |

Tags: design features combination design features

Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C

2013-04-22 13:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibbs investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1. Language: English Contact HTML: MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: c agreement trial combination